[go: up one dir, main page]

PE20080197A1 - Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s) - Google Patents

Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)

Info

Publication number
PE20080197A1
PE20080197A1 PE2007000142A PE2007000142A PE20080197A1 PE 20080197 A1 PE20080197 A1 PE 20080197A1 PE 2007000142 A PE2007000142 A PE 2007000142A PE 2007000142 A PE2007000142 A PE 2007000142A PE 20080197 A1 PE20080197 A1 PE 20080197A1
Authority
PE
Peru
Prior art keywords
absent
same
protease inhibitor
treatment methods
hcv protease
Prior art date
Application number
PE2007000142A
Other languages
English (en)
Inventor
Xiao Tong
Bruce A Malcolm
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080197A1 publication Critical patent/PE20080197A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN COMPUESTO DE FORMULA I, DONDE Y ES ALQUILO, HETEROALQUILO, HETEROARILO, ENTRE OTROS; Z ES O, N, CH, ENTRE OTROS; W ES C=O, C=S, SO2, C(=N-CN) O PUEDE ESTAR AUSENTE; Q ES CH, N, P, ENTRE OTROS O PUEDE ESTAR AUSENTE; M ES O, S, SO2, ENTRE OTROS O PUEDE ESTAR AUSENTE; A ES O, CH2, S, SO2, ENTRE OTROS; E ES CH, N, O UNA UNION DOBLE HACIA A, L O G; G ES (CH2)p, (CHR)p; (CRR') O PUEDE ESTAR AUSENTE; J ES (CH2)p; (CHR)p, SO2, NH, ENTRE OTROS O PUEDE ESTAR AUSENTE; L ES CH, CR, O, S NR O PUEDE ESTAR AUSENTE; p ES 0-6; R, R', R2, R3 Y R4 SON CADA UNO ALQUILO C1-C10, ALQUENILO C2-C10, CICLOALQUILO C3-C8, HETEROCICLOALQUILO C3-C8, ENTRE OTROS; B) AL MENOS UN INHIBIDOR DE POLIMERASA DEL HCV DISTINTO DE HVC-796 TAL COMO BENZOTIDIAZINA. DICHA COMPOSICION PUEDE CONTENER ADEMAS UN INTERFERON, RIBAVIRINA, ENTRE OTROS. UN COMPUESTO PREFERIDO ES Ia. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE HCV (VIRUS DE LA HEPATITIS C)
PE2007000142A 2006-02-09 2007-02-09 Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s) PE20080197A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77192706P 2006-02-09 2006-02-09
US84129806P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
PE20080197A1 true PE20080197A1 (es) 2008-04-11

Family

ID=38258834

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000142A PE20080197A1 (es) 2006-02-09 2007-02-09 Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)

Country Status (9)

Country Link
US (1) US20070274951A1 (es)
EP (1) EP1981524A2 (es)
JP (1) JP2009526070A (es)
AR (1) AR059429A1 (es)
CA (1) CA2641859A1 (es)
MX (1) MX2008010355A (es)
PE (1) PE20080197A1 (es)
TW (1) TW200800265A (es)
WO (1) WO2007092616A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US20070287664A1 (en) * 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
CN101611002A (zh) * 2006-12-22 2009-12-23 先灵公司 用于治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
JP5079818B2 (ja) 2006-12-22 2012-11-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
TW200924751A (en) * 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
CA2697454C (en) * 2007-08-29 2015-11-03 Schering Corporation 2-carboxy substituted indole derivatives and methods of use thereof
MX2010002318A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
ATE519503T1 (de) * 2007-09-14 2011-08-15 Schering Corp Verfahren zur behandlung von patienten mit hepatitis c
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
US8940688B2 (en) * 2007-12-05 2015-01-27 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide HCV serine protease inhibitors
WO2009094438A1 (en) * 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide hcv serine protease inhibitors
MX2010008109A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
WO2009117594A1 (en) * 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
WO2009126444A2 (en) * 2008-04-09 2009-10-15 Alsp American Life Science Pharmaceuticals, Inc. Compositions for the treatment of neurodegenerative conditions and methods for the use thereof
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR073603A1 (es) * 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
WO2010031832A2 (en) * 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
WO2010117936A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
US20120244122A1 (en) * 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US20130171103A1 (en) * 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CA2813093A1 (en) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2012332832A1 (en) * 2011-10-31 2014-04-17 Msd Italia S.R.L. Compositions useful for the treatment of viral diseases
EP2897611B1 (en) * 2012-09-18 2019-07-24 AbbVie Inc. Methods for treating hepatitis c
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
KR20180032578A (ko) * 2015-06-30 2018-03-30 아이거 그룹 인터내셔널, 인코포레이티드 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤
DE69709671T2 (de) * 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
JP4452401B2 (ja) * 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
ATE461207T1 (de) * 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
CA2487346A1 (en) * 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
WO2005067454A2 (en) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection

Also Published As

Publication number Publication date
WO2007092616A3 (en) 2007-10-04
AR059429A1 (es) 2008-04-09
WO2007092616A2 (en) 2007-08-16
EP1981524A2 (en) 2008-10-22
JP2009526070A (ja) 2009-07-16
US20070274951A1 (en) 2007-11-29
TW200800265A (en) 2008-01-01
MX2008010355A (es) 2008-10-31
CA2641859A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
PE20080197A1 (es) Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
PE20070106A1 (es) Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr
PE20050999A1 (es) Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20050370A1 (es) Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c
PE20120207A1 (es) Derivados de naftaleno, como inhibidores de hcv ns5a
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
PE20121432A1 (es) Combinaciones de un inhibidor especifico de ns5a del hcv e inhibidor de proteasa ns3 del hcv
AR047793A1 (es) Inhibidores de la serina proteasa ns-3 del vhc
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
RU2010102229A (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
UY29703A1 (es) "inhibidores macrocíclicos del virus de la hepatitis c"
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
CO6220960A2 (es) Compuesto de piperazina novedoso y uso del mismo como inhibidor de polimerasa del virus de la hepatitis c
CR8595A (es) Inhibidor del dipeptidil-peptidasa
PE20081792A1 (es) Inhibidores de serina proteasas
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
NO20080879L (no) HCV-NS3-proteaseinhibitorer
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20020691A1 (es) PEPTIDOS DIARILICOS COMO INHIBIDORES DE LA NS3/NS4a SERINA PROTEASA DEL VIRUS DE LA HEPATITIS C

Legal Events

Date Code Title Description
FA Abandonment or withdrawal